PARP1 and cancer: Given that myeloid cells -mainly dendritic cells (DC), neutrophils (PMN), and macrophages (Mac)-play crucial roles in both inflammation and cancer progression, and that their functional polarization can shape the immune contexture of the tumor microenvironment (TME) [10] and many clinical studies demonstrated that tumor-associated macrophages and neutrophils affect the therapeutic outcome [11,12,13], it is critical to understand how PARP inhibition may impact these populations.